Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

16 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Microglia innately develop within cerebral organoids.
Ormel PR, Vieira de Sá R, van Bodegraven EJ, Karst H, Harschnitz O, Sneeboer MAM, Johansen LE, van Dijk RE, Scheefhals N, Berdenis van Berlekom A, Ribes Martínez E, Kling S, MacGillavry HD, van den Berg LH, Kahn RS, Hol EM, de Witte LD, Pasterkamp RJ. Ormel PR, et al. Among authors: johansen le. Nat Commun. 2018 Oct 9;9(1):4167. doi: 10.1038/s41467-018-06684-2. Nat Commun. 2018. PMID: 30301888 Free PMC article.
Anti-C2 Antibody ARGX-117 Inhibits Complement in a Disease Model for Multifocal Motor Neuropathy.
Budding K, Johansen LE, Van de Walle I, Dijkxhoorn K, de Zeeuw E, Bloemenkamp LM, Bos JW, Jansen MD, Curial CAD, Silence K, de Haard H, Blanchetot C, Van de Ven L, Leusen JHW, Pasterkamp RJ, van den Berg LH, Hack CE, Boross P, van der Pol WL. Budding K, et al. Among authors: johansen le. Neurol Neuroimmunol Neuroinflamm. 2021 Nov 10;9(1):e1107. doi: 10.1212/NXI.0000000000001107. Print 2022 Jan. Neurol Neuroimmunol Neuroinflamm. 2021. PMID: 34759020 Free PMC article.
The Neurolipid Atlas: a lipidomics resource for neurodegenerative diseases uncovers cholesterol as a regulator of astrocyte reactivity impaired by ApoE4.
Feringa FM, Hertog SJK, Wang L, Derks RJE, Kruijff I, Erlebach L, Heijneman J, Miramontes R, Pömpner N, Blomberg N, Olivier-Jimenez D, Johansen LE, Cammack AJ, Giblin A, Toomey CE, Rose IVL, Yuan H, Ward M, Isaacs AM, Kampmann M, Kronenberg-Versteeg D, Lashley T, Thompson LM, Ori A, Mohammed Y, Giera M, van der Kant R. Feringa FM, et al. Among authors: johansen le. bioRxiv [Preprint]. 2024 Jul 3:2024.07.01.601474. doi: 10.1101/2024.07.01.601474. bioRxiv. 2024. PMID: 39005258 Free PMC article. Preprint.
Triple combination targeting PI3K, ER, and CDK4/6 inhibits growth of ER-positive breast cancer resistant to fulvestrant and CDK4/6 or PI3K inhibitor.
Karimi L, Alves CL, Terp MG, Tuttolomondo M, Portman N, Ehmsen S, Johansen LE, Bak M, Lim E, Ditzel HJ. Karimi L, et al. Among authors: johansen le. Cancer Commun (Lond). 2023 Jun;43(6):720-725. doi: 10.1002/cac2.12425. Epub 2023 Apr 26. Cancer Commun (Lond). 2023. PMID: 37101393 Free PMC article. No abstract available.
Quantitative Phosphoproteomics of the Angiotensin AT2-Receptor Signaling Network Identifies HDAC1 (Histone-Deacetylase-1) and p53 as Mediators of Antiproliferation and Apoptosis.
Peluso AA, Kempf SJ, Verano-Braga T, Rodrigues-Ribeiro L, Johansen LE, Hansen MR, Kitlen G, Haugaard AH, Sumners C, Ditzel HJ, Santos RA, Bader M, Larsen MR, Steckelings UM. Peluso AA, et al. Among authors: johansen le. Hypertension. 2022 Nov;79(11):2530-2541. doi: 10.1161/HYPERTENSIONAHA.121.18620. Epub 2022 Sep 9. Hypertension. 2022. PMID: 36082664
Publisher Correction: Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer.
Alves CL, Ehmsen S, Terp MG, Portman N, Tuttolomondo M, Gammelgaard OL, Hundebøl MF, Kaminska K, Johansen LE, Bak M, Honeth G, Bosch A, Lim E, Ditzel HJ. Alves CL, et al. Among authors: johansen le. Nat Commun. 2021 Sep 16;12(1):5588. doi: 10.1038/s41467-021-25901-z. Nat Commun. 2021. PMID: 34531405 Free PMC article. No abstract available.
Co-targeting CDK4/6 and AKT with endocrine therapy prevents progression in CDK4/6 inhibitor and endocrine therapy-resistant breast cancer.
Alves CL, Ehmsen S, Terp MG, Portman N, Tuttolomondo M, Gammelgaard OL, Hundebøl MF, Kaminska K, Johansen LE, Bak M, Honeth G, Bosch A, Lim E, Ditzel HJ. Alves CL, et al. Among authors: johansen le. Nat Commun. 2021 Aug 25;12(1):5112. doi: 10.1038/s41467-021-25422-9. Nat Commun. 2021. PMID: 34433817 Free PMC article.
MCM3 upregulation confers endocrine resistance in breast cancer and is a predictive marker of diminished tamoxifen benefit.
Løkkegaard S, Elias D, Alves CL, Bennetzen MV, Lænkholm AV, Bak M, Gjerstorff MF, Johansen LE, Vever H, Bjerre C, Kirkegaard T, Nordenskjöld B, Fornander T, Stål O, Lindström LS, Esserman LJ, Lykkesfeldt AE, Andersen JS, Leth-Larsen R, Ditzel HJ. Løkkegaard S, et al. Among authors: johansen le. NPJ Breast Cancer. 2021 Jan 4;7(1):2. doi: 10.1038/s41523-020-00210-8. NPJ Breast Cancer. 2021. PMID: 33398005 Free PMC article.
16 results